Protective mechanisms of head and neck squamous cell carcinomas from immune assault.

T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res (2008) 1.63

Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res (2008) 1.32

Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck (2009) 1.25

Immune suppression in head and neck cancers: a review. Clin Dev Immunol (2011) 1.17

Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun (2008) 1.09

Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J Immunother (2010) 0.94

Immunotherapy of head and neck cancer: current and future considerations. J Oncol (2009) 0.93

Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement. Immunology (2013) 0.92

Intratumoral dendritic cells and chemoradiation for the treatment of murine squamous cell carcinoma. J Immunother (2008) 0.90

Effect of the premalignant and tumor microenvironment on immune cell cytokine production in head and neck cancer. Cancers (Basel) (2014) 0.89

Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. Cancer Lett (2007) 0.89

Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck (2012) 0.88

Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol (2014) 0.88

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother (2011) 0.87

Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. Head Neck Oncol (2013) 0.86

Tumors induce the formation of suppressor endothelial cells in vivo. Cancer Immunol Immunother (2010) 0.86

A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother (2014) 0.84

USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics. Oral Oncol (2011) 0.83

Lentiviral vector-based therapy in head and neck cancer (Review). Oncol Lett (2013) 0.83

A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunol Immunother (2011) 0.79

Head and neck cancers manifested as deep neck infection. Eur Arch Otorhinolaryngol (2011) 0.77

Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells. Anticancer Res (2016) 0.77

Effect of treatment on systemic cytokines in head and neck squamous cell carcinoma patients. Results Immunol (2011) 0.76